A Registry and Biospecimen Collection to Advance the Diagnosis and Care of Patients with Glomerular Diseases


About this study

The purpose of this registry is to establish a database of patients diagnosed with minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), or immunoglobulin A nephropathy (IgAN), to advance the diagnosis and care of patients with glomerular diseases.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Diagnosis of MCD, FSGS, MN, or IgAN on first diagnostic kidney biopsy, per specified pathology definitions
    • First diagnostic kidney biopsy within 5 years of study enrollment
    • Access to first kidney biopsy report and/or slides
  • All ages
  • Willing to comply with study requirements, including intention to fully participate in protocol-specified follow-up at a clinical study site
  • Informed consent and, where age appropriate, informed assent 

 Exclusion Criteria

  • ESKD, defined as chronic dialysis or kidney transplant 
  • Institutionalized
  • Solid organ or bone marrow transplant recipient at time of first kidney biopsy
  • Diagnosis of any of the following at the time of first diagnostic kidney biopsy
    • Diabetes mellitus 
    • Systemic lupus erythematosus
    • HIV infection
    • Active malignancy, except for non-melanoma skin cancer
    • Active Hepatitis B or C infection, defined as positive viral load

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Fernando Fervenza, M.D., Ph.D.

Closed for enrollment

More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer